Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Sonida Senior Living (SNDA) has drawn attention after recent share price moves, with the stock’s past year and past 3 months returns standing out against its longer term five year track record.
See our latest analysis for Sonida Senior Living.
With the latest share price at $35.07, Sonida Senior Living’s recent 1 day share price return of 4.34% sits alongside a 90 day share price return of 11.02% and a 1 year total shareholder return of 48.79%. This suggests momentum has been building over the shorter term, even as the 5 year total shareholder return of a 16.50% loss points to a more mixed long term picture.
If this rebound in senior living has your attention, it could be a good moment to broaden your search and check out our 33 healthcare AI stocks as another way to spot potential ideas in related areas.
After a 1-year total return of nearly 49%, and with the shares now trading above the latest analyst price target of $31.50, an important question arises: Is Sonida still undervalued, or is the market already pricing in future growth?
On a simple yardstick, Sonida Senior Living’s P/S ratio of 4.9x sits well above both the wider US Healthcare industry average of 1.2x and its peer group at 1x, even though the company is still loss making.
The P/S ratio compares the company’s market value to its revenue, so a higher multiple usually means investors are willing to pay more for each dollar of sales, often when they expect stronger growth, higher quality revenue, or a future swing into profitability.
For Sonida, current forecasts point to revenue increasing around 5.3% per year. This trails the 10.4% forecast for the broader US market and is below the 20% threshold often associated with high growth names. At the same time, the company remains unprofitable, with a reported net loss of $76.416 million and a negative return on equity of 128.86%. Losses have been reduced over the past five years, and the SWS fair P/S estimate sits much lower at 0.6x, a level the market could move toward if sentiment cools.
Compared to both its industry and peer averages, the current 4.9x P/S looks elevated. Any investor weighing this stock is effectively paying a premium multiple relative to similar healthcare names for revenue that is forecast to grow more slowly than the wider market.